全文获取类型
收费全文 | 370574篇 |
免费 | 25951篇 |
国内免费 | 7139篇 |
专业分类
耳鼻咽喉 | 4747篇 |
儿科学 | 10885篇 |
妇产科学 | 7628篇 |
基础医学 | 29883篇 |
口腔科学 | 8057篇 |
临床医学 | 41750篇 |
内科学 | 45587篇 |
皮肤病学 | 4702篇 |
神经病学 | 25497篇 |
特种医学 | 8471篇 |
外国民族医学 | 35篇 |
外科学 | 37819篇 |
综合类 | 53262篇 |
一般理论 | 29篇 |
预防医学 | 37865篇 |
眼科学 | 5952篇 |
药学 | 32956篇 |
703篇 | |
中国医学 | 32383篇 |
肿瘤学 | 15453篇 |
出版年
2023年 | 6042篇 |
2022年 | 8761篇 |
2021年 | 13692篇 |
2020年 | 15423篇 |
2019年 | 24691篇 |
2018年 | 16764篇 |
2017年 | 14202篇 |
2016年 | 11310篇 |
2015年 | 10507篇 |
2014年 | 21823篇 |
2013年 | 24037篇 |
2012年 | 19805篇 |
2011年 | 21325篇 |
2010年 | 17111篇 |
2009年 | 15815篇 |
2008年 | 15441篇 |
2007年 | 15869篇 |
2006年 | 13846篇 |
2005年 | 11939篇 |
2004年 | 9760篇 |
2003年 | 8627篇 |
2002年 | 6717篇 |
2001年 | 6029篇 |
2000年 | 4931篇 |
1999年 | 4213篇 |
1998年 | 3254篇 |
1997年 | 3102篇 |
1996年 | 2669篇 |
1995年 | 2767篇 |
1994年 | 2664篇 |
1993年 | 2138篇 |
1992年 | 2167篇 |
1991年 | 1850篇 |
1990年 | 1655篇 |
1989年 | 1465篇 |
1988年 | 1390篇 |
1987年 | 1213篇 |
1985年 | 3858篇 |
1984年 | 4855篇 |
1983年 | 3379篇 |
1982年 | 3842篇 |
1981年 | 3587篇 |
1980年 | 3183篇 |
1979年 | 2926篇 |
1978年 | 2551篇 |
1977年 | 1916篇 |
1976年 | 2158篇 |
1975年 | 1638篇 |
1974年 | 1429篇 |
1973年 | 1282篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Tyler B. Kratzer MPH Ahmedin Jemal DVM PhD Kimberly D. Miller MPH Sarah Nash PhD Charles Wiggins PhD Diana Redwood PhD Robert Smith PhD Rebecca L. Siegel MPH 《CA: a cancer journal for clinicians》2023,73(2):120-146
American Indian and Alaska Native (AIAN) individuals are diverse culturally and geographically but share a high prevalence of chronic illness, largely because of obstacles to high-quality health care. The authors comprehensively examined cancer incidence and mortality among non-Hispanic AIAN individuals, compared with non-Hispanic White individuals for context, using population-based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Overall cancer rates among AIAN individuals were 2% higher than among White individuals for incidence (2014 through 2018, confined to Purchased/Referred Care Delivery Area counties to reduce racial misclassification) but 18% higher for mortality (2015 through 2019). However, disparities varied widely by cancer type and geographic region. For example, breast and prostate cancer mortality rates are 8% and 31% higher, respectively, in AIAN individuals than in White individuals despite lower incidence and the availability of early detection tests for these cancers. The burden among AIAN individuals is highest for infection-related cancers (liver, stomach, and cervix), for kidney cancer, and for colorectal cancer among indigenous Alaskans (91.3 vs. 35.5 cases per 100,000 for White Alaskans), who have the highest rates in the world. Steep increases for early onset colorectal cancer, from 18.8 cases per 100,000 Native Alaskans aged 20–49 years during 1998 through 2002 to 34.8 cases per 100,000 during 2014 through 2018, exacerbated this disparity. Death rates for infection-related cancers (liver, stomach, and cervix), as well as kidney cancer, were approximately two-fold higher among AIAN individuals compared with White individuals. These findings highlight the need for more effective strategies to reduce the prevalence of chronic oncogenic infections and improve access to high-quality cancer screening and treatment for AIAN individuals. Mitigating the disparate burden will require expanded financial support of tribal health care as well as increased collaboration and engagement with this marginalized population. 相似文献
2.
3.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
4.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
5.
6.
Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial
Areej El-Jawahri MD Marlise R. Luskin MD Joseph A. Greer PhD Lara Traeger PhD Mitchell Lavoie BS Dagny Marie Vaughn BS Stephanie Andrews BS Daniel Yang BS Kofi Y. Boateng BS Richard A. Newcomb MD Nneka N. Ufere MD Amir T. Fathi MD Gabriela Hobbs MD Andrew Brunner MD Gregory A. Abel MD Richard M. Stone MD Daniel J. DeAngelo MD PhD Martha Wadleigh MD Jennifer S. Temel MD 《Cancer》2023,129(7):1075-1084
7.
8.
9.
Dikshat Gopal Gupta PhD Neelam Varma MD Praveen Sharma MD Mihai I. Truica MD PhD Sarki A. Abdulkadir MD PhD Parmod Singh PhD Man Updesh Singh Sachdeva MD Shano Naseem MD Mohammad Rizwan Siddiqui PhD Parveen Bose MSc Jogeshwar Binota MSc Pankaj Malhotra MD Alka Khadwal MD Amita Trehan Subhash Varma MD 《Cancer》2023,129(21):3390-3404
10.
Mathew Vithayathil Scott Smith Mingyang Song 《International journal of cancer. Journal international du cancer》2023,152(6):1085-1094
Serrated polyps (SPs) are precursors to one-third of colorectal cancers (CRCs), with histological subtypes: hyperplastic polyps (HPs), sessile serrated lesions (SSLs) and traditional serrated adenomas (TSAs). The incidence of early-onset CRC before the age of 50 is increasing, with limited understanding of SPs in younger cohorts. Using a large colonoscopy-based cohort, we characterized epidemiologic profiles of SP subtypes, compared to conventional adenomas, with secondary analysis on early-onset polyps. Ninety-four thousand four hundred and twenty-seven patients underwent screening colonoscopies between 2010 and 2018. Demographic, endoscopic and histopathologic characteristics of each polyp subtype were described. High-risk polyps included SSLs ≥10 mm/with dysplasia and conventional adenomas ≥10 mm/with tubulovillous/villous histology/high-grade dysplasia. We examined polyp prevalence with age and compared early- (age < 50) and late-onset polyps (age ≥ 50). Eighteen thousand one hundred and twenty-five patients had SPs (4357 SSLs, 15 415 HPs, 120 TSAs) and 26 699 had conventional adenomas. High-risk SSLs were enriched in the ascending colon (44.1% vs 2.6-35.8% for other locations; P < .003). Early- and late-onset SPs had similar subsite distribution. Early-onset conventional adenomas were more enriched in the distal colon/rectum (51.8% vs 43.4%, P < .001). Multiple conventional adenomas were more represented in late-onset groups (40.8% vs 33.8%, P < .001), with no difference in SSLs. The prevalence of conventional adenomas/high-risk conventional adenomas increased continuously with age, whereas the prevalence of SSLs/high-risk SSLs was stable from age 40 years onwards. A higher proportion of women were diagnosed with early-onset than late-onset SSLs (62.9% vs 57.6%, P = .03). Conventional adenomas, SSLs, early- and late-onset polyps have distinct epidemiology. The findings have implications for improved colonoscopy screening and surveillance and understanding the etiologic heterogeneity of CRC. 相似文献